Numerous studies of PARP-1 involvement in oxidative stress-associated endothelial dysfunction, primarily using cell culture and ex vivo systems, have demonstrated that pharmacological inhibition of PARP-1 confers protection against such dysfunction (for review[19], [23]). This evidence concerns the gene PARP1 and endothelial dysfunction.